Skip to main content
. 2017 May 4;8(39):64853–64866. doi: 10.18632/oncotarget.17614

Figure 1. CB2 agonist promoted survival of engrafted AD-MSCs in ischemic myocardium.

Figure 1

A. Longitudinal BLI tracked the survival and retention of AD-MSCs survival in vivo (n = 8 for each group). Colored scale bar represents BLI radiance intensity in p/s/cm 2/sr. B. Quantitative analysis of A. C. Ex vivo Fluc enzymatic activity of infarcted myocardium on POD 14 (n = 5). . *P < 0.05 versus AD-MSCs.